Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist.

Adjuvant medical treatment steroid therapy of polyarteritis nodosa. Specific treatments are sometimes required. 55: 146–155 renal vasculitis. Angiotensin converting enzyme inhib-10. Guillevin L, Jarrousse B, Lok C et al. Long-term followup after itors or angiotensin II-receptor blockers are effective treatment of polyarteritis nodosa and Churg–Strauss angiitis and able to control severe or malignant hypertension. with comparison of steroids, plasma exchange and cyclophos-phamide to steroids and plasma exchange. A prospective ran-Chronic renal failure may occur several months or domized trial of 71 patients. The Cooperative Study Group for years after recovery from PAN and is attributable to Polyarteritis Nodosa. polyarteritis nodosa and Churg–Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients can prevent deformities and enable functional posi-recovery may occur several months after the onset of and management of the vasculitides. Baillere's Clin Rheumatol the treatment. Treatment of good-prognosis polyarteritis nodosa and Churg–Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in U ¨ ber eine nicht bisher beschriebene cyclophosphamide and plasma exchanges versus corticosteroids eigenthü mliche Arterienerkrankung (Periarteritis Nodosa), die plus pulse cyclophosphamide alone in the treatment of polyarter-mit Morbus Brightii und rapid fortschreitender allgemeiner itis nodosa and Churg–Strauss syndrome patients with factors Muskellähmung einhergeht. deficiency virus-related vasculitis. Clinical presentation of and 6. Guillevin L, Lhote F, Cohen P et al. Polyarteritis nodosa related therapeutic approach to eight cases. Ann Méd Interne (Paris) to hepatitis B virus. A prospective study with long-term observa-Antineutrophil cyto-involvement in polyarteritis nodosa and Churg–Strauss syn-plasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Recent studies have shown that HCV may increase the